Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis

Exclusion Criteria

• •Patients with non-active secondary progressive MS and primary progressive MS.
• •Any disease other than MS that may better explain the signs and symptoms, including history of complete transverse myelitis.
• •Clinical signs or presence of laboratory findings suggestive for neuromyelitis optica (NMO) spectrum disorders or myelin oligodendrocyte glycoprotein (MOG)-IgG-associated encephalomyelitis
• •Any active and uncontrolled coexisting autoimmune disease, other than MS (except for type 1 diabetes mellitus and inflammatory bowel disease)
• •Use of experimental/investigational drug (with the exception ofCOVID-19 vaccines approved by emergency use authorization) and/or participation in drug clinical studies within 6 months prior to Screening
• •Previous or current use of MS treatments lifelong, or within a pre-specified time period.
• •Use of the pre-specified concomitant medications.
• •Clinically significantly abnormal and pre-specified lab values.
• •History of chronic systemic infections within 6 months before the date of informed consent.
• •Diagnosis or suspected liver function impairment, which may cause fluctuating liver function tests during this study.
• •Known history of nephrolithiasis or underlying condition with a strong association of nephrolithiasis.
• •History or clinical diagnosis of gout.
• •History or presence of any major medical or psychiatric illness
• •Substantial medical condition that could create undue risk to the patient, could affect adherence with the study protocol or could undesirably affect study outcomes